Roche	**SIX-MONTHLY SUSAR REPORT No. 1056688**
Author(s)	Nathalie Cambon, Nicole Mairon, Birgit Jaber, Vineeta Malik, Aakanksha Bisht, Renu Bhardwaj
Reviewer(s)	Patricia Lehane, Rodney Smith, Manjeet Singh
Department	Product Development, Regulatory, Roche Products Ltd, Welwyn Garden City, AL7 1TW, UK
Medicinal Product	Rituximab/RO452294
Report Data	Open Label
Interval Covered by This Report	26 May 2013 to 25 November 2013 (inclusive)

SSR approval date: See last date in electronic signature manifestation below.

SSR approved by: See electronic signature manifestation below.

Name	Reason for Signing	Date and Time (UTC)
Arguinzoniz,Miguel	Associate Safety Science Cluster Head	18-Dec-2013 16:42:16

The information contained in this document is proprietary and confidential and is intended for the exclusive use of the designated addressee. Any disclosure, reproduction, distribution or other dissemination of this information is strictly prohibited

During the current review period, 26 May 2013 to 25 November 2013 (inclusive), the Sponsor submitted 49 Suspected Unexpected Serious Adverse Reactions (SUSARs) for rituximab. There were also 14 non–company Investigational Medicinal Product (IMP) SUSARs.

Section 2 of the current report details the new safety information which has been added to the Developmental Core Safety Information (DCSI) of the Investigator Brochure (IB) for rituximab. During the review period no Adverse Drug Reactions (ADRs) were added to the DCSI.

After review of the clinical details of the appended SUSARs, the Sponsor concludes that no changes to the conduct of the ongoing clinical trials with rituximab are warranted. Based on the information presented in this Six-Monthly SUSAR Report, the benefit-risk of rituximab remains unchanged.

The information contained in this document is proprietary and confidential and is intended for the exclusive use of the designated addressee. Any disclosure, reproduction, distribution or other dissemination of this information is strictly prohibited

1. INTRODUCTION

This summary report is written in accordance with the European Clinical Trials Directive (2001/20/EC) and the June 2011 *Detailed Guidance on the Collection, Verification and Presentation of Adverse Event (AE)/Reaction Reports Arising from Clinical Trials on Medicinal Products for Human Use ('CT-3')*.

All Suspected Unexpected Serious Adverse Reactions (SUSARs) identified by the Sponsor during the reporting interval 26 May 2013 to 25 November 2013 inclusive, are included in this six-monthly report.

1.1 METHODOLOGY

The attached six-monthly line listing includes all potential SUSARs identified during the reporting period for rituximab, as well as for non–company Investigational Medicinal Products (IMPs) used in trials with rituximab [1] (where applicable)[2]. The listing includes both initial and follow-up SUSAR reports.

The line listing is sorted by indication, based on the Medical Dictionary for Regulatory Activities (MedDRA) version 16.1 preferred term included in the single case report. Separate sections are presented under each indication for SUSARs to rituximab, and SUSARs to non–company IMPs and comparators (where applicable). Within each of these sections, cases are presented by Adverse Event Report (AER) number.

The rituximab Investigator's Brochure (IB) version 17.0, dated July 2012 for oncology indications containing Developmental Core Safety Information (DCSI) version 4.0, dated May 2012 was used as the safety reference document during the review period till July 2013. In July 2013, IB was updated to version 18.0 containing DCSI version 6.0 (dated July 2013) and was used as the safety reference document for the remaining review period.

The rituximab IB for subcutaneous formulation version 4.0, dated February 2013 (containing DCSI version 5.0, dated February 2013) was used as the safety reference document till July 2013. In July 2013 addendum No.1 (containing DCSI version 6.0, dated July 2013) was added to the IB for subcutaneous formulation and was used as the safety reference document for the remaining review period.

The rituximab IB version 12.0, dated May 2013 for autoimmune indications containing DCSI version 3.0 (dated February 2013) was used as the safety reference document during the review period. Additionally, in May 2013, addendum No.1 and in September

[1] Where rituximab is the primary IMP in the trial.

[2] In the appended SSR line listing, the safety reference document for bendamustine in AER 1011018 appears as the IB. This case has been corrected on the safety database to reflect EU-SPC as the safety reference document for bendamustine.

2013 addendum No. 2 was added to IB for autoimmune disease, version 12.0 and was used as the safety reference document for the remaining review period.

The DCSI details which events are to be considered expected. The DCSI will be updated with only those events evaluated by the Sponsor and preliminarily identified as suspected Adverse Drug Reactions (ADRs).

Additionally, for clinical trials that are conducted according to the label, and where the local label is used as the safety reference document by the Investigator (BO21223, BO21004, BO21005, ML21685 and GO27834), the Sponsor assesses listedness against its Core Data Sheet (CDS) for rituximab.

As the CDS is not automatically updated following individual SUSAR reports, the SUSARs reported during the review period for which the CDS was used as the reference document will still be considered unexpected.

The bendamustine, cyclophosphamide, doxorubicin, prednisolone and vincristine Summary of Product Characteristics (SPCs) were used as the safety reference documents for the SUSARs to non–company IMPs bendamustine, cyclophosphamide, doxorubicin, prednisolone and vincristine during the review period.

In the line-listing, both the causality assessment of the reporter and the Sponsor are provided for each SUSAR. Roche's medical assessment of causality is based on the information in the individual SUSAR report. This assessment does not represent a full evaluation of all similar cases and epidemiological data of the therapeutic population. The internal causality assessment of an event to the use of a drug is not intended to suggest, imply or admit that a causal relationship exists between the AE and the use of the drug. Rather, this field is labeled as such from a European regulatory assessment standpoint, which indicates that such events could merely be consistent with an association.

The AEs where the causal relationship to the IMP is assessed by the reporter or the Sponsor as unknown will be considered by Roche to be suspected adverse reactions for reporting purposes and thus may be included as SUSARs in this report. Details of the drug-event relationship for each SUSAR are shown in the appended SUSAR line listing.

2. UPDATE OF REFERENCE DOCUMENTS

No changes to study documentation were necessitated by the SUSARs presented in the attached line listing.

During the reporting period, the DCSI for rituximab (oncology indication) was updated from version 4.0 to 6.0 and DSCI for rituximab subcutaneous formulation was updated from version 5.0 to 6.0. Cumulative changes in DCSI are described below:

- Version 5.0 of the DCSI was issued in February 2013 at the time of the annual update of the IB for the subcutaneous formulation of rituximab (oncology indications). The updated DCSI included recommendations related to the management of skin reactions (Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome) and incorporated safety information related to the SC formulation.

- In version 6.0 of the DCSI, wording on preventing hepatitis B reactivation has been strengthened based on the current data and updated guidelines; recommendations for screening, monitoring, and management of hepatitis B reactivation with rituximab have been updated. Additionally, recommendations related to the management of skin reactions have been clarified.

During the reporting period, the DCSI for rituximab (autoimmune indication) was updated, with new safety information. The DCSI update from version 3.0 to version 4.0 involved the following changes:

- Based on the current data and updated guidelines, wording on preventing hepatitis B reactivation has been strengthened. Recommendations for screening, monitoring, and management of hepatitis B reactivation with rituximab have been updated.

- The wording on management of severe skin reactions such as Toxic Epidermal Necrolysis and Stevens-Johnson syndrome was clarified.

3. CONCLUSION

After review of the clinical details of the appended SUSARs, the Sponsor concludes that no changes to the conduct of the ongoing clinical trials with rituximab are warranted. Based on the information presented in this Six-Monthly SUSAR Report, the benefit-risk of rituximab remains unchanged.

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. AER No. (Ver. No.) EudraCT No. Site No. Patient No. Country Age Sex	**Suspect Medication # = SUSAR Drug**	**Route Regimen**	**Treatment Start/Stop or Duration**	**Medical History**	**SUSAR Reported Term Preferred Term (Onset Date)**	**Drug-Event Relationship: Reporter Causality Company Causality Ref. Doc. Event Outcome (Resolved Date)**
MO25455 1092238(9.0) 2010-023407-95 230990 230990001 FRANCE 60 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x750mg / -- -- Intravenous (not otherwise specified) --x700mg / -- --	07MAY2012/ -- 02JUL2012/ --	Anxiety Myalgia Hypertension Migraine Hypercholesterolaemia	ABDOMINAL LOCAL SITE INJECTION REACTION Injection site reaction [SUSAR Drugs 1, 2] (01JUN2012)	Related Related IB Recovered/resolved (21JUN2012)
	2 # RHUPH20/ RITUXIMAB	Subcutaneous --x1400mg / -- --	04JUN2012/ --			
BO21223 1164538(4.0) 2010-024132-41 230817 50469 CANADA 75 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 4 Weeks	25JUL2012/ --	Atrial fibrillation Hypertension Blood cholesterol increased Diarrhoea Mitral valve stenosis Nausea Cerebrovascular accident prophylaxis Sacroiliitis Cerebrovascular accident Tonsillectomy Appendicectomy Female sterilisation	CARDIOGENIC SHOCK Cardiogenic shock (24NOV2012)	Related Related CDS Recovered/resolved (06DEC2012)
	2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x---- / 4 Weeks	25JUL2012/ --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO25455 1206182(6.0) 2010-023407-95 236878 236878003 FRANCE 72 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x630mg / -- --	18APR2012/ --	Chills Herpes zoster Vomiting Neutropenia Tinnitus	ANAL TUMOR MALIGNANT Anal cancer [SUSAR Drugs 1, 2] (03DEC2012)	Related Related IB Not recovered/not resolved
	2 # RHUPH20/ RITUXIMAB	Subcutaneous 1x1400mg / 1 Months Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- --	30MAY2012/ 13DEC2012 27JUN2012/ -- 22AUG2012/ -- 07NOV2012/ --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
GO27834 1219843(11.0) 2011-004377-84 251850 21951 USA 65 Years Female	**1 # DCDT2980S (ANTI-CD22-VC-M MAE)**	Intravenous (not otherwise specified) 1x---- / 21 Days	18APR2013/ --	Neuropathy peripheral Gastrooesophageal reflux disease Osteoporosis Nausea Fatigue Renal impairment Retroperitoneal fibrosis Hydronephrosis Pyrexia Hyperhidrosis Arthritis Herpes zoster Squamous cell carcinoma Herpes zoster Deep vein thrombosis	CHRONIC RENAL FAILURE Renal failure chronic [SUSAR Drugs 1] (26APR2013) UROSEPSIS Urosepsis [SUSAR Drugs 1, 2] (08MAY2013)	Related Related IB Not recovered/not resolved Related Related IB/CDS Fatal
	2 # RITUXIMAB	Intravenous (not otherwise specified) 1x---- / 21 Days	17APR2013/ --			
MO25455 1222287(3.0) 2010-023407-95 233752 233752002 ITALY 74 Years Male	**1 # RITUXIMAB**	Unknown 1x---- / 28 Days Unknown -- Intravenous (not otherwise specified) 1x667mg / 28 Days	NOV2009/ JAN2010 JAN2011/ 10MAY2011 27NOV2012/ --	Anxiety Depression Interstitial lung disease Tobacco user	LUNG CANCER Lung neoplasm malignant (07MAR2013)	Related Related IB Not recovered/not resolved
	2 BENDAMUSTINE	Subcutaneous --x160mg / -- --	28NOV2012/ 21MAR2013			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
	3 CHLORPHENIRAMINE MALEATE	Intravenous (not otherwise specified) 1x---- / 28 Days	27NOV2012/ 21MAR2013			
	4 HYDROCORTISONE	Intravenous (not otherwise specified) --x200mg / -- --	27NOV2012/ --			
	5 GRANISETRON HYDROCHLORIDE	Intravenous (not otherwise specified) --x3mg / -- --	28NOV2012/ 21MAR2013			
	6 LORATADINE	Oral --x10mg / -- --	02JAN2013/ 21MAR2013			
	7 PREDNISONE	Unknown -- Oral --x25mg / -- -- Unknown --	JAN2011/ 10MAY2011 02JAN2013/ 21MAR2013 NOV2009/ JAN2010			
	8 CYCLOPHOSPHAMIDE	Unknown --	NOV2009/ JAN2010			
	9 DOXORUBICIN	Unknown --	NOV2009/ JAN2010			
	10 VINCRISTINE	Unknown --	NOV2009/ JAN2010			
	11 DEXAMETHASONE	Unknown --	-- --			
	12 CYTARABINE	Unknown --	-- --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
	13 OXALIPLATIN	Unknown --	-- --			
GO27834 1224209(6.0) 2011-004377-84 251850 21950 USA 57 Years Female	**1 # DCDS4501A (ANTI-CD79B-VC-MMAE)**	Intravenous (not otherwise specified) 1x---- / 21 Days	09APR2013/ --	Thrombocytopenia Asthma Fatigue Dyspnoea exertional Nausea Gastrooesophageal reflux disease Anaemia Constipation Insomnia Hypertension Migraine Breast cancer	NEUTROPENIC FEVER Febrile neutropenia [SUSAR Drugs 1] (12MAY2013) HEPATOMEGALY Hepatomegaly [SUSAR Drugs 1, 2] (12MAY2013) DIFFUSE FATTY INFILTRATION (LIVER) Hepatic steatosis [SUSAR Drugs 1, 2] (12MAY2013)	Related Related IB Recovered/resolved (23MAY2013) Related Related IB/CDS Recovered/resolved (23MAY2013) Related Related IB/CDS Recovered/resolved (23MAY2013)
	2 # RITUXIMAB	Intravenous (not otherwise specified) 1x---- / 21 Days	08APR2013/ --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO25455 1243717(6.0) 2010-023407-95 236217 236217002 NORWAY 69 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x731mg / -- --	20DEC2012/ --	Hypertension Weight increased Pain Calculus urinary	CEREBRAL HEMORRHAGE Cerebral haemorrhage [SUSAR Drugs 1, 2] (18JUN2013)	Related Related IB Fatal
	2 # RHUPH20/ RITUXIMAB	Subcutaneous 1x1400mg / 1 Months Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- -- Subcutaneous --x1400mg / -- --	17JAN2013/ -- 19FEB2013/ -- 19MAR2013/ -- 16APR2013/ -- 14MAY2013/ -- 11JUN2013/ --			
	3 ASPIRIN	Unknown --	01JAN2007/ 25JUN2013			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. AER No. (Ver. No.) EudraCT No. Site No. Patient No. Country Age Sex	**Suspect Medication # = SUSAR Drug**	**Route Regimen**	**Treatment Start/Stop or Duration**	**Medical History**	**SUSAR Reported Term Preferred Term (Onset Date)**	**Drug-Event Relationship: Reporter Causality Company Causality Ref. Doc. Event Outcome (Resolved Date)**
BO22334 1249694(5.0) 2010-021377-36 205058 1319 ITALY 66 Years Female	**1 # RHUPH20/ RITUXIMAB**	Subcutaneous 1x---- / 2 Months	07JUL2011/ --	Asthenia Anxiety	PROBABLY CREUTZFELDT-JACOB DISEASE Creutzfeldt-Jakob disease (MAY2013)	Related Related IB Fatal
BO21223 1252512(0.0) 2010-024132-41 209416 54414 UNITED KINGDOM 88 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 4 Weeks	13JUN2013/ --	Fluid retention Stasis dermatitis Squamous cell carcinoma	SYNCOPE Syncope (22JUL2013)	Related Related CDS Recovered/resolved (22JUL2013)
	2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x---- / 4 Weeks	13JUN2013/ --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
GO27834 1253015(9.0) 2011-004377-84 251703 21752 USA 58 Years Male	**1 # DCDT2980S (ANTI-CD22-VC-MMAE)**	Intravenous (not otherwise specified) 1x---- / 21 Days	20JUN2013/ --	Hypercholesterolaemia Iron deficiency anaemia Hernia repair Knee operation Tonsillectomy Deep vein thrombosis	PERFORATED DUODENUM Duodenal perforation [SUSAR Drugs 1] (23JUL2013) SEPSIS Sepsis [SUSAR Drugs 1, 2] (13AUG2013)	Related Related IB Recovering/resolving (--) Related Related IB/CDS Fatal
	2 # RITUXIMAB	Intravenous (not otherwise specified) 1x---- / 21 Days	19JUN2013/ --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO22334 1255335(0.0) 2010-021377-36 205554 1046 AUSTRALIA 74 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --	03AUG2011/ --	Anxiety Depression Vitamin B12 deficiency Hypothyroidism Insomnia Dry eye Urinary tract infection Nausea Osteoarthritis Skin lesion Enteritis Herpes zoster Scoliosis Large intestine polyp Uterine polyp Neuralgia Hypertonic bladder Diverticulum	SKIN LESION (DERMATOLOGY/SKIN OTHER)- INVASIVE SQUAMOUS CELL CARCINOMA Squamous cell carcinoma of skin (15MAY2013)	Related Related IB Not recovered/not resolved

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO25455 1259406(6.0) 2010-023407-95 246343 246343008 ITALY 72 Years Male	**1 # RHUPH20/ RITUXIMAB** **2 # RITUXIMAB**	Subcutaneous 1x1400mg / 3 Weeks Subcutaneous 1x1400mg / 3 Weeks Subcutaneous 1x1400mg / 3 Weeks Subcutaneous 1x1400mg / 3 Weeks Subcutaneous 1x1400mg / 3 Weeks Intravenous (not otherwise specified) --x640mg / -- --	17MAY2013/ -- 17MAY2013/ -- 07JUN2013/ -- 28JUN2013/ -- 19JUL2013/ -- 22APR2013/ --		PNEUMOCYSTIS JIROVECI PNEUMONIA Pneumocystis jirovecii pneumonia [SUSAR Drugs 1, 2] (29JUL2013)	Related Related IB Fatal

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO22334 1264818(1.0) 2010-021377-36 205443 1184 BRAZIL 60 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --	-- --	Hypertension Diabetes mellitus Ascites	FEBRILE NEUTROPENIA Febrile neutropenia [SUSAR Drugs 1, 2] (20AUG2013)	Related Related IB Fatal
	2 # RHUPH20/ RITUXIMAB	Subcutaneous 1x1400mg / 21 Days	15MAY2013/ --			
	3 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	4 VINCRISTINE	Unknown --	-- --			
	5 PREDNISOLONE	Unknown --	-- --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21223 1267011(1.0) 2010-024132-41 235686 56260 JAPAN 65 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	09JUL2013/ --	Hypertension Spinal column stenosis Spinal osteoarthritis	SUSPECT OF GUILLAIN-BARRE SYNDROME Guillain-Barre syndrome (12AUG2013)	Related Related CDS Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	10JUL2013/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	10JUL2013/ --			
	4 VINCRISTINE	-- 1x---- / 3 Weeks	-- --			
	5 PREDNISOLONE	Oral 1x---- / 3 Weeks	09JUL2013/ --			
ML20101 1283494(0.0) 2005-005473-29 200 358 GERMANY 63 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x750mg / -- --	22JUL2013/ --		CHOLECYSTITIS Cholecystitis (13SEP2013)	Related Related IB Recovering/resolving (--)

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1284008(3.0) 2012-003230-17 252089 252089001 GERMANY 70 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x860mg / -- --	12SEP2013/ --	Hepatic cyst Benign prostatic hyperplasia Leukoplakia oral	GOUT Gout (05OCT2013) FALL Fall (27SEP2013)	Related Related IB Recovering/resolving (--) Related Related IB Not Applicable (--)
	2 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	3 DOXORUBICIN	Unknown --	-- --			
	4 VINCRISTINE	Unknown --	-- --			
	5 PREDNISONE	Unknown --	-- --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28457 1297668(0.0) 2012-003230-17 253182 253182006 KOREA, REPUBLIC OF 58 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x375mg/m2 / -- --	18OCT2013/ --		ESOPHAGITIS Oesophagitis (28OCT2013)	Related Related IB Recovering/resolving (--)
	2 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	3 DOXORUBICIN	Unknown --	-- --			
	4 VINCRISTINE	Unknown --	-- --			
	5 PREDNISOLONE	Unknown --	-- --			

RITUXIMAB; RHUPH20

Indication: B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21223 1303405(1.0) 2010-024132-41 209861 54813 UNITED KINGDOM 61 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 4 Weeks	08JUL2013/ --		HYPERCALCEMIA Hypercalcaemia (11NOV2013)	Related Related CDS Recovering/resolving (--)
	2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x---- / 4 Weeks	08JUL2013/ --			

Indication: B-CELL LYMPHOMA - SUSARs to non-company IMPs and Comparators

NO SUSARS WERE IDENTIFIED

RITUXIMAB; RHUPH20

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML21561 1226873(0.0) EVCT-999999-25 -- QEH101 AUSTRALIA 68 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x1100mg / 4 Weeks	17AUG2011/ --		MELANOMA Malignant melanoma (26FEB2013)	Related Related IB Recovered/resolved (26MAR2013)
	2 FLUDARABINE PHOSPHATE	Oral --x50mg / -- --	17AUG2011/ --			
	3 CYCLOPHOSPHAMIDE	Oral --x350mg / -- --	17AUG2011/ --			
BO21004 1242620(0.0) 2009-012476-28 204826 7470 GERMANY 70 Years Not specified	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x1136mg / -- --	29NOV2011/ --		BASAL CELL CARCINOMA Basal cell carcinoma (JAN2013)	Related Related CDS Not Reported
	2 CHLORAMBUCIL	Oral --	-- --			

RITUXIMAB; RHUPH20

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO25341 1268105(3.0) 2010-021380-32 205437 2422 BRAZIL 60 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --	23APR2013/ --	Hypertension Osteoarthritis Dyslipidaemia Nausea	NEUTROPENIC COLITIS Neutropenic colitis (27AUG2013)	Related Related IB Recovered/resolved (18SEP2013)
ML18429 1279759(2.0) EVCT-999999-25 -- 4 VENEZUELA, BOLIVARIAN REPUBLIC OF 69 Years Male	**1 # RITUXIMAB** 2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x375mg / 1 Days Unknown --	23AUG2013/ -- -- --	Diabetes mellitus	NOSOCOMIAL PNEUMONIA Pneumonia (28SEP2013)	Related Related IB Fatal

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs to non-company IMPs and Comparators

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs to non-company IMPs and Comparators

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO22468 1011018(9.0) 2009-012072-28 207530 3 TURKEY 55 Years Male	1 RITUXIMAB	Intravenous (not otherwise specified) 1x900mg / 1 Months	15JUN2011/ --		VESTIBULAR DISORDER Vestibular disorder (06OCT2011)	Related Related IB Not recovered/not resolved
	2 # **BENDAMUSTINE**	Intravenous (not otherwise specified) 1x320mg / 1 Months	15JUN2011/ --			
MO22468 1024240(13.0) 2009-012072-28 167451 167451022 UNITED KINGDOM 69 Years Female	1 RITUXIMAB	Intravenous (not otherwise specified) 1x800mg / 1 Months Intravenous (not otherwise specified) 1x800mg / 1 Months	16NOV2011/ -- 18JAN2012/ --	Hypertension Atrial fibrillation	DIZZINESS Dizziness (17DEC2011)	Related Related EU-SPC Recovering/resolving (--)
	2 # **BENDAMUSTINE**	Intravenous (not otherwise specified) 1x150mg / 1 Months Intravenous (not otherwise specified) 1x300mg / 1 Months	17NOV2011/ -- 18JAN2012/ --			

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs to non-company IMPs and Comparators

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO22468 1043359(11.0) 2009-012072-28 167209 5 FRANCE 78 Years Female	1 RITUXIMAB	Intravenous (not otherwise specified) 1x619mg / 1 Days Intravenous (not otherwise specified) --	07FEB2012/ -- 22FEB2012/ --	Hypertension Atrial fibrillation Anaemia Thrombocytopenia Neutropenia	FEBRILE PANCYTOPENIA Pancytopenia (21FEB2012)	Related Related EU-SPC Recovered/resolved with se (27FEB2012)
	2 # **BENDAMUSTINE**	Intravenous (not otherwise specified) 1x116mg / 1 Days	07FEB2012/ --			
ML25464 1300801(0.0) EVCT-999999-25 208534 006 ISRAEL 66 Years Male	1 RITUXIMAB	Intravenous (not otherwise specified) 1x375mg/m2 / 1 Total Intravenous (not otherwise specified) 1x900mg / 28 Days	23JUN2013/ -- -- --	Crohn's disease Hypothyroidism Diabetes mellitus Benign prostatic hyperplasia	NEUTROPENIA AND FEVER Febrile neutropenia (28AUG2013)	Unknown Related EU-SPC Recovered/resolved (08SEP2013)
	2 FLUDARABINE PHOSPHATE	Intravenous (not otherwise specified) 1x22.7mg / 28 Days	24JUN2013/ --			
	3 # **CYCLOPHOSPHAMID E**	Intravenous (not otherwise specified) 1x270mg / 28 Days	24JUN2013/ --			

Indication: CHRONIC LYMPHOCYTIC LEUKAEMIA - SUSARs to non-company IMPs and Comparators

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO22468 786197(6.0) 2009-012072-28 167214 5 FRANCE 60 Years Male	1 RITUXIMAB	Intravenous (not otherwise specified) --x708.75mg / -- --	11MAY2011/ 11MAY2011	Pyrexia Pancytopenia Oedema peripheral Chronic lymphocytic leukaemia	FEBRILE PANCYTOPENIA Pancytopenia (22JUN2011)	Related Related EU-SPC Not recovered/not resolved
	2 # **BENDAMUSTINE**	Intravenous (not otherwise specified) 2x170.1mg / 28 Days	11MAY2011/ 12MAY2011			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1013184(7.0) 2010-024194-39 209518 13353 THAILAND 62 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	04NOV2011/ --		FEBRILE NEUTROPENIA Febrile neutropenia (12NOV2011)	Related Related CDS Fatal
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x1027.5mg / 3 Weeks	04NOV2011/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x68.5mg / 3 Weeks	04NOV2011/ --			
	4 VINCRISTINE	Intravenous (not otherwise specified) 1x1.92mg / 3 Weeks	04NOV2011/ --			
	5 PREDNISOLONE	Oral 1x100mg / 3 Weeks	04NOV2011/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1208341(2.0) 2010-024194-39 209520 13455 THAILAND 71 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	21AUG2012/ --	Hypertension	UNEXPLAINED DEATH Death (--)	Related Related CDS Fatal
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	21AUG2012/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	21AUG2012/ --			
	4 VINCRISTINE	Intravenous bolus 1x---- / 3 Weeks	21AUG2012/ --			
	5 PREDNISONE	Unknown 1x---- / 3 Weeks	21AUG2012/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1215014(6.0) 2012-000669-19 248024 248024001 SPAIN 63 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x592mg / -- --	03APR2013/ --	Hypersensitivity Asthma Anxiety Gastritis Oesophagitis Biopsy bone Asthenia Biopsy stomach	FEBRILE NEUTROPENIA Febrile neutropenia [SUSAR Drugs 1, 2] (16MAY2013)	Related Related IB Fatal
	2 # RHUPH20/ RITUXIMAB	Subcutaneous --x1400mg / -- --	24APR2013/ --			
	3 CYCLOPHOSPHAMIDE	Unknown --x750mg / -- -- Unknown --x750mg / -- --	04APR2013/ -- 24APR2013/ --			
	4 DOXORUBICIN	Unknown --x50mg / -- -- Unknown --x50mg / -- --	04APR2013/ -- 24APR2013/ --			
	5 VINCRISTINE	Unknown --x2mg/m2 / -- -- Unknown --x2mg/m2 / -- --	04APR2013/ -- 24APR2013/ --			
	6 PREDNISOLONE	Unknown --x100mg / -- -- Unknown --x100mg / -- --	04APR2013/ -- 08MAY2013/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1232241(1.0) 2012-000669-19 249881 249881003 NETHERLANDS 62 Years Female	**1 # RHUPH20/ RITUXIMAB**	Subcutaneous 1x1400mg / 1 Days	28MAY2013/ --	Candida infection Abdominal pain Osteoarthritis Tachycardia	NEUTROPENIC FEVER Febrile neutropenia [SUSAR Drugs 1, 2] (02JUN2013)	Related Related IB Fatal
	2 # RITUXIMAB	Intravenous (not otherwise specified) --x800mg / -- --	14MAY2013/ --			
	3 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x1600mg / 1 Days	28MAY2013/ --			
		Intravenous (not otherwise specified) --x1600mg / -- --	14MAY2013/ --			
	4 DOXORUBICIN	Intravenous (not otherwise specified) 1x105mg / 1 Days	28MAY2013/ --			
		Intravenous (not otherwise specified) --x105mg / -- --	14MAY2013/ --			
	5 VINCRISTINE SULFATE	Intravenous (not otherwise specified) 1x1.4mg/m2 / 1 Days	28MAY2013/ --			
		Intravenous (not otherwise specified) --x1.4mg/m2 / -- --	14MAY2013/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
	6 PREDNISONE	Unknown --x500Unit Not Reported / -- -- Unknown --	14MAY2013/ -- 28MAY2013/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1238779(1.0) 2010-024194-39 230789 10354 CANADA 67 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	24AUG2011/ 26JAN2012	Asthma Type 2 diabetes mellitus Hypertension Oedema peripheral Nausea Insomnia Glaucoma Benign prostatic hyperplasia Blood cholesterol increased Haemorrhoids Sensory loss Back pain Constipation Dysuria	ACUTE MYELOID LEUKEMIA Acute myeloid leukaemia (14JUN2013)	Related Related CDS Fatal
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	24AUG2011/ 16DEC2011			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	24AUG2011/ 16DEC2011			
	4 VINCRISTINE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	24AUG2011/ 16DEC2011			
	5 PREDNISONE	Oral 1x---- / 3 Weeks	24AUG2011/ 20DEC2011			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1255312(1.0) 2010-024194-39 231805 10555 CANADA 60 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	-- --	Asthma exercise induced Abdominal pain Fatigue Night sweats Testicular swelling Weight decreased Musculoskeletal chest pain	CHOLECYSTITIS Cholecystitis (30JUL2013)	Not Reported Unknown CDS Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	-- --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	-- --			
	4 VINCRISTINE	Intravenous bolus 1x---- / 3 Weeks	-- --			
	5 PREDNISOLONE	Oral 1x---- / 3 Weeks	-- --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1256034(8.0) 2012-000669-19 248944 248944005 COLOMBIA 73 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x705mg / -- --	25JUL2013/ --	Hypertension Diabetes mellitus Oesophagitis Hernia repair Tracheostomy Endoscopy	SEPTIC SHOCK Septic shock [SUSAR Drugs 1, 2] (03NOV2013)	Related Related IB Fatal
	2 # RHUPH20/ RITUXIMAB	Subcutaneous 1x1400mg / 21 Days	03SEP2013/ --			
	3 CYCLOPHOSPHAMIDE	Unknown 1x1410mg / 21 Days	25JUL2013/ 25OCT2013			
	4 DOXORUBICIN	Unknown 1x94mg / 21 Days	25JUL2013/ 25OCT2013			
	5 VINCRISTINE	Unknown 1x2mg / 2 Days	25JUL2013/ --			
	6 PREDNISOLONE	Unknown --x100mg / -- --	25JUL2013/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1258559(0.0) 2012-000669-19 250139 250139003 THAILAND 64 Years Male	**1 # RHUPH20/ RITUXIMAB**	Subcutaneous 1x1400mg / 3 Weeks	01MAY2013/ --		FEBRILE NEUTROPENIA Febrile neutropenia (03AUG2013)	Related Related IB Fatal
	2 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	3 DOXORUBICIN	Unknown --	-- --			
	4 VINCRISTINE	Unknown --	-- --			
	5 PREDNISOLONE	Unknown --	-- --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21005 1258930(0.0) 2010-024194-39 230750 14404 USA 75 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 3 Weeks	30JUL2013/ --	Chronic obstructive pulmonary disease, Atrial fibrillation, Coronary artery disease, Hypertension, Gastrooesophageal reflux disease, Irritable bowel syndrome, Colitis, Hyperlipidaemia, Peripheral arterial occlusive disease, Cerebrovascular disorder, Hypothyroidism, Anaemia, Arteriosclerosis, Hypercalcaemia, Hypomagnesaem, Blood creatinine increased, Lymphopenia, Hyperglycaemia, Hypoalbuminaemia, Hyperuricaemia, Blood lactate dehydrogenase increased, Leukopenia, Hyperkalaemia, Asthenia, Fatigue, Dyspnoea, Anxiety, Dizziness, Dizziness, Decreased appetite, Diarrhoea, Rash, Night sweats, Pain, Fibromyalgia, Oedema peripheral, Hypotension, Hyponatraemia, Cerebrovascular accident	HYPONATREMIA Hyponatraemia (06AUG2013)	Related Related CDS Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 3 Weeks	30JUL2013/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 3 Weeks	30JUL2013/ --			
	4 VINCRISTINE	-- 1x---- / 3 Weeks	30JUL2013/ --			
	5 PREDNISOLONE	Oral 1x---- / 3 Weeks	30JUL2013/ --			
MO28107 1281686(0.0) 2012-000669-19 247529 247529009 ITALY -- Not specified	**1 # RHUPH20/ RITUXIMAB**	Subcutaneous --	-- --		MUCOSITIS Mucosal inflammation [SUSAR Drugs 1, 2] (08MAY2013)	Related Related IB Not Reported
	2 # RITUXIMAB	Intravenous (not otherwise specified) --	-- --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1283951(0.0) 2012-000669-19 251228 251228004 CANADA 71 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x375mg/m2 / -- --	18SEP2013/ --	Lung neoplasm malignant Hypertension Emphysema Cardiovascular disorder Hypothyroidism Anxiety Anaemia Syncope Ear infection Gastrooesophageal reflux disease	COLIC INFLAMMATION (COLITIS) Colitis (27SEP2013)	Related Related IB Not recovered/not resolved
	2 CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) 1x---- / 21 Days	18SEP2013/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) 1x---- / 21 Days	18SEP2013/ --			
	4 VINCRISTINE	Intravenous (not otherwise specified) 1x---- / 21 Days	18SEP2013/ --			
	5 PREDNISONE	Oral 1x---- / 21 Days	18SEP2013/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO28107 1287344(0.0) 2012-000669-19 246140 246140001 ARGENTINA 79 Years Female	**1 # RHUPH20/ RITUXIMAB**	Subcutaneous 1x562mg / 21 Days	26SEP2013/ 26SEP2013	Vertigo Diverticulum intestinal Hypertension Irritable bowel syndrome Duodenal ulcer	HYPONATREMIA Hyponatraemia [SUSAR Drugs 1, 2] (07OCT2013)	Related Related IB Recovering/resolving (--)
	2 # RITUXIMAB	Intravenous (not otherwise specified) --	-- --			
	3 CYCLOPHOSPHAMIDE	Unknown --	-- --			
	4 DOXORUBICIN	Unknown --	-- --			
	5 VINCRISTINE SULFATE	Unknown --	-- --			
	6 PREDNISONE	Unknown --	-- --			
MO28457 1297748(0.0) 2012-003230-17 -- 257287007 INDONESIA 69 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) --x550mg / -- --	17OCT2013/ --	Hypertension	FEBRILE NEUTROPENIA Febrile neutropenia (28OCT2013)	Related Related IB Fatal

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs to non-company IMPs and Comparators

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO18261 1241084(0.0) 2005-005229-68 24 461 GERMANY -- Female	1 RITUXIMAB	Unknown --	06OCT2010/ --		MDS Myelodysplastic syndrome [SUSAR Drugs 2, 3, 4, 5] (--)	Related Related EU-SPC Not Reported
	2 # CYCLOPHOSPHAMIDE	Unknown --	06OCT2010/ --			
	3 # DOXORUBICIN	Unknown --	06OCT2010/ --			
	4 # PREDNISOLONE	Unknown --	06OCT2010/ --			
	5 # VINCRISTINE	Unknown --	06OCT2010/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs to non-company IMPs and Comparators

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO18261 1291990(1.0) EVCT-999999-25 337 538 GERMANY 74 Years Male	1 RITUXIMAB	Intravenous (not otherwise specified) --x738.75mg / -- --	17JUN2011/ --	Benign prostatic hyperplasia Urinary tract infection	URINARY TRACT INFECTION Urinary tract infection [SUSAR Drugs 2, 4] (18JUL2011) FEVER Pyrexia [SUSAR Drugs 3, 4] (14AUG2011)	Related Related EU-SPC Recovered/resolved (25JUL2011) Related Related EU-SPC Recovered/resolved (26AUG2011)
	2 # VINCRISTINE	Intravenous (not otherwise specified) --x2mg / -- --	18JUN2011/ --			
	3 # PREDNISOLONE	Oral --x100mg / -- --	10JUN2011/ --			
	4 # CYCLOPHOSPHAMIDE	Intravenous (not otherwise specified) --x1477.5mg / -- --	18JUN2011/ --			
	5 DOXORUBICIN	Intravenous (not otherwise specified) --x98.5mg / -- --	18JUN2011/ --			

RITUXIMAB; RHUPH20

Indication: DIFFUSE LARGE B-CELL LYMPHOMA - SUSARs to non-company IMPs and Comparators

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
MO18261 1293161(0.0) 2005-005229-68 17 447 GERMANY 75 Years Female	1 RITUXIMAB	Intravenous (not otherwise specified) --x375mg/m2 / -- --	02SEP2010/ --		PULMONARY INFECTION Lung infection (15OCT2010)	Related Related EU-SPC Recovered/resolved (--)
	2 # CYCLOPHOSPHAMIDE	Unknown --	03SEP2010/ --			
	3 DOXORUBICIN	Intravenous (not otherwise specified) --x50mg/m2 / -- --	03SEP2010/ --			

RITUXIMAB; RHUPH20

Indication: MALIGNANT LYMPHOID NEOPLASM - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML21685 1261720(0.0) 2008-005859-16 233 71576 GERMANY 46 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x626mg / 2 Months	11JAN2013/ 22JUL2013	Neutropenia	PORT SYSTEM ASSOCIATED THROMBOSIS Thrombosis in device (22JUL2013)	Related Related CDS Not recovered/not resolved
	2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x300mg / 28 Days	25APR2012/ --			

Indication: MALIGNANT LYMPHOID NEOPLASM - SUSARs to non-company IMPs and Comparators

NO SUSARS WERE IDENTIFIED

RITUXIMAB; RHUPH20

Indication: MANTLE CELL LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
ML20493 601221(2.0) 2006-004093-27 90954 912 HUNGARY 73 Years Male	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x375mg/m2 / 3 Week Intravenous (not otherwise specified) --x720mg / -- --	21OCT2008/ -- 02DEC2008/ --	Hypertonia Mantle cell lymphoma Pleurisy Urticaria Urticaria Listeriosis Infectious pleural effusion Mantle cell lymphoma	PNEUMOTHORAX Pneumothorax (04DEC2008) HEART FAILURE Cardiac failure (04DEC2008)	Related Related IB Not recovered/not resolved Related Related IB Fatal
	2 CYCLOPHOSPHAMIDE	Unknown --x1440mg / -- --	02DEC2008/ --			
	3 DOXORUBICIN	Unknown --x96mg / -- --	02DEC2008/ --			
	4 VINCRISTINE	Unknown --x2mg / -- --	02DEC2008/ --			
	5 METHYLPREDNISOLONE	Unknown --x801mg / -- --	02DEC2008/ --			

Indication: MANTLE CELL LYMPHOMA - SUSARs to non-company IMPs and Comparators

NO SUSARS WERE IDENTIFIED

RITUXIMAB; RHUPH20

Indication: NON-HODGKIN'S LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
GO27834 1173952(7.0) 2011-004377-84 252343 21100 USA 69 Years Male	**1 # DCDT2980S (ANTI-CD22-VC-M MAE)**	Intravenous (not otherwise specified) 1x338mg / 21 Days	07DEC2012/ 02JAN2013	Renal failure chronic Type 2 diabetes mellitus Atrial fibrillation Hypertension Osteoarthritis Coronary artery disease Dyslipidaemia Gout Benign prostatic hyperplasia Hypoacusis Rash Dyspnoea Neuropathy peripheral Asthenia Arthralgia Pollakiuria Oedema	ABNORMAL CREATININE Blood creatinine abnormal [SUSAR Drugs 1] (20DEC2012) ABNORMAL PROTHROMBIN TIME Prothrombin time abnormal [SUSAR Drugs 1, 2] (20DEC2012) ABNORMAL GLUCOSE Blood glucose abnormal [SUSAR Drugs 1, 2] (20DEC2012) ABNORMAL ACTIVATED PARTIAL THROMBOPLASTIN TIME Activated partial thromboplastin time abnormal [SUSAR Drugs 1, 2] (20DEC2012) ABNORMAL INTERNATIONAL NORMALISED RATIO International normalised ratio abnormal [SUSAR Drugs 1, 2] (20DEC2012)	Related Related IB Not Reported Related Related IB/CDS Not Reported Related Related IB/CDS Not Reported Related Related IB/CDS Not Reported Related Related IB/CDS Not Reported

RITUXIMAB; RHUPH20

Indication: NON-HODGKIN'S LYMPHOMA - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
					(20DEC2012) ACUTE RENAL FAILURE Renal failure acute [SUSAR Drugs 1] (20DEC2012)	Related Related IB Recovering/resolving (--)
	2 # RITUXIMAB	Intravenous (not otherwise specified) 1x934mg / 21 Days	06DEC2012/ 02JAN2013			
	3 LISINOPRIL	Oral --x40mg / -- --	2000/ --			

Indication: NON-HODGKIN'S LYMPHOMA - SUSARs to non-company IMPs and Comparators

NO SUSARS WERE IDENTIFIED

RITUXIMAB; RHUPH20

Indication: NON-HODGKIN'S LYMPHOMA UNSPECIFIED HISTOLOGY INDOLENT - SUSARs

Protocol No. **AER No. (Ver. No.)** **EudraCT No.** **Site No.** **Patient No.** **Country** **Age** **Sex**	**Suspect Medication** **# = SUSAR Drug**	**Route** **Regimen**	**Treatment** **Start/Stop** **or Duration**	**Medical** **History**	**SUSAR** **Reported Term** **Preferred Term** **(Onset Date)**	**Drug-Event** **Relationship:** **Reporter Causality** **Company Causality** **Ref. Doc.** **Event Outcome** **(Resolved Date)**
BO21223 1235308(0.0) 2010-024132-41 209317 51107 GERMANY 56 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) 1x---- / 4 Weeks	09APR2013/ --		INCREASED CREATININE Blood creatinine increased (05JUN2013)	Related Related CDS Recovered/resolved (08JUN2013)
	2 BENDAMUSTINE	Intravenous (not otherwise specified) 1x---- / 4 Weeks	10APR2013/ --			

Indication: NON-HODGKIN'S LYMPHOMA UNSPECIFIED HISTOLOGY INDOLENT - SUSARs to non-company IMPs and Comparators

NO SUSARS WERE IDENTIFIED

RITUXIMAB; RHUPH20

Indication: RHEUMATOID ARTHRITIS - SUSARs

Protocol No. AER No. (Ver. No.) EudraCT No. Site No. Patient No. Country Age Sex	**Suspect Medication # = SUSAR Drug**	**Route Regimen**	**Treatment Start/Stop or Duration**	**Medical History**	**SUSAR Reported Term Preferred Term (Onset Date)**	**Drug-Event Relationship: Reporter Causality Company Causality Ref. Doc. Event Outcome (Resolved Date)**
U3839G 625788(3.0) -- -- S159171007 USA 28 Years Female	**1 # RITUXIMAB**	Intravenous (not otherwise specified) -- Intravenous (not otherwise specified) 1x1000mg / 6 Months	20FEB2008/ 04MAY2009 20FEB2008/ 04MAY2009	Device related infection	ARDS Acute respiratory distress syndrome (26MAR2009) RITUXAN INDUCED ACUTE PNEUMONITIS Pneumonitis (26MAR2009)	Related Related IB Recovered/resolved (04MAY2009) Related Related IB Recovered/resolved (04MAY2009)
U3839G 714276(2.0) EVCT-999999-25 -- S162031001 USA 73 Years Female	**1 # RITUXIMAB** 2 PREDNISONE	Intravenous (not otherwise specified) --x1000mg / -- -- Oral --x5mg / -- --	19MAR2007/ -- -- --		DUODENAL ULCERS Duodenal ulcer (26APR2010) GASTRITIS Gastritis (26APR2010)	Related Related IB Recovered/resolved (10MAY2010) Related Related IB Recovered/resolved (10MAY2010)

Indication: RHEUMATOID ARTHRITIS - SUSARs to non-company IMPs and Comparators

NO SUSARS WERE IDENTIFIED

Dataset Parameters	
Dataset Name	25NOV2013_SSR_RO452294_RE RUN
Date range (Informed Date)	from 26MAY2013 to 25NOV2013
Report Parameters	
SSR Drug	RITUXIMAB;RITUXIMAB HALOZYME
Unblinded Report?	No